Pharma giant Roche has completed the sale of its solid and liquid formulation facility in Segrate, Italy, to CMO Delpharm, which reached a deal to supply the…
Thermo Fisher Scientific has completed its $7.2 billion acquisition of CDMO Patheon, weeks after Lonza completed its $5.5 billion buyout of Capsugel.
Three major regulatory bodies – FDA, EMA and Health Canada – changed their guidelines to drug naming. How could these changes impact drug launch timelines?
Three weeks after announcing it would cut 350 jobs at two plants in Israel, Teva has already adjusted that number to 285.
India-based Alembic Pharmaceuticals is selling its formulation manufacturing plant in Baddi to Scott Edil Pharmacia for an undisclosed amount.
Shareholders of India’s Gland Pharma, an injectables manufacturer, are said to be considering selling a 74% stake to China’s Fosun Pharma as a hedge against…
Trump wants to lower the tax burden for companies bringing cash back to the U.S. from overseas, but repatriation may not spur M&A.
Swiss CDMO Lonza forecast in its half-year earnings report it will produce about $7.9 billion in annual revenues by 2022, strengthened by the recent purchase…
Australia’s TPI Enterprises has struck a deal to buy the opioid and CMO tablet businesses of Norway’s Vistin Pharma.
AGC Asahi Glass, which bought CMC Biologics this year, will make its Seattle, Washington, area operation the headquarters of its drug business.
CDMO Patheon is investing $45 million in four sites that stretch from the West Coast of the U.S. to Italy.